61% of India's population prefer purchasing medicines online

11 July 2016

Around 61% of Indians prefer to purchase medicines online, according to a survey conducted by Consumer Online Foundation and market research firm, BRIEF (Bureau of Research on Industry and Economic Fundamentals).

Tighter regulation needs to be in place not only for online sales but also brick and mortar stores, say the Foundation, according to a web posting by Brand India Pharma, a unit of India’s Pharmaceutical Export Promotion Council (Pharmexcil).

The results also revealed that around 50% of the population bought medicines from the chemist without prescription and 36% confirmed that they had never received any bills.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK